Literature DB >> 26191263

Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis.

Xin-Ke Zhang1, Ying-Ying Wang2, Jie-Wei Chen1, Tao Qin3.   

Abstract

Papillary urothelial neoplasm of low malignant potential (PUNLMP) had the incidence of low and definitive recurrence. Therefore, few studies showed that the relationship between pathological factors and the prognosis of patients with PUNLMP. The aim of this study assessed the linkage of pathological factors and prognosis of patients with PUNLMP including the presence or absence of mitoses and the thickness of urothelium. A retrospective analysis of 71 patients with PUNLMP was enrolled between January 2007 and June 2013. The clinicopathological factors consisting of tumor diameter, multifocality, the presence or absence of mitoses and cell thickness of urothelium were retrieved, Log-rank test and Cox proportional hazards regression models were used for univariate and multivariate analyses to evaluate the associations of these factors with recurrence-free survival (RFS) and progression-free survival (PFS).The incidence of recurrence and progression for PUNLMP was 19.7% and 16.9%, respectively. Patients with grade progression represented 85.7% in the recurrent patients. No patients had stage progression and no cases died from invasive urothelial carcinoma. Univariate analysis showed that the presence of mitoses, tumor diameter greater than or equal to 0.8 cm, multifocality were significantly correlated with worse RFS (P<0.05) and PFS (P<0.05). Multivariate analysis demonstrated that the presence of mitoses, tumor multifocality were significantly independent biomarkers for worse RFS (P<0.05) and PFS (P<0.05). Although the rare and infrequent mitoses were found for PUNLMP, the presence of mitoses and tumor multifocality were still the independent and poor predictors for the prognosis of PUNLMP. In addition, once the PUNLMP appeared to the recurrence, the inevitable grade progression could be determined, herein, long-term follow-up was necessary to be warranted, especially for patients with multiple lesions and the presence of mitoses.

Entities:  

Keywords:  PUNLMP; mitoses; multifocality; progression; recurrence

Mesh:

Year:  2015        PMID: 26191263      PMCID: PMC4503134     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  17 in total

1.  Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.

Authors:  J W A Oosterhuis; R F M Schapers; M L G Janssen-Heijnen; R P E Pauwels; D W Newling; F ten Kate
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Recurrence and progression in low grade papillary urothelial tumors.

Authors:  S Holmäng; H Hedelin; C Anderström; E Holmberg; C Busch; S L Johansson
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

Review 3.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

4.  Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia.

Authors:  S J Cina; K J Lancaster-Weiss; K Lecksell; J I Epstein
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

5.  Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.

Authors:  A Alsheikh; Z Mohamedali; E Jones; J Masterson; C B Gilks
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

6.  Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.

Authors:  S Holmäng; P Andius; H Hedelin; K Wester; C Busch; S L Johansson
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

7.  Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential.

Authors:  Y Fujii; S Kawakami; F Koga; T Nemoto; K Kihara
Journal:  BJU Int       Date:  2003-10       Impact factor: 5.588

8.  Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.

Authors:  Achille Pich; Luigi Chiusa; Andrea Formiconi; Diego Galliano; Paola Bortolin; Alberto Comino; Roberto Navone
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

9.  Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression.

Authors:  Hemamali Samaratunga; Danil V Makarov; Jonathan I Epstein
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

10.  Grading of superficial bladder cancer by quantitative mitotic frequency analysis.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; R Terho; H Haapasalo
Journal:  J Urol       Date:  1993-01       Impact factor: 7.450

View more
  2 in total

Review 1.  Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification.

Authors:  Ivonne A Montes-Mojarro; Saki Hassas; Sina Staehle; Philip Sander; Niklas Harland; Lina Maria Serna-Higuita; Irina Bonzheim; Hans Bösmüller; Arnulf Stenzl; Falko Fend
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

2.  Assessment of Histopathological Parameters Useful in the Diagnosis of Low Grade Non-Invasive Urothelial Carcinomas.

Authors:  A Ș Săndulescu; A E Stepan; C Mărgăritescu; A E Crișan; C E Simionescu
Journal:  Curr Health Sci J       Date:  2019-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.